OM vs. NVRO, TCMD, SKIN, NYXH, DRTS, ELMD, RCEL, CATX, INGN, and LAKE
Should you be buying Outset Medical stock or one of its competitors? The main competitors of Outset Medical include Nevro (NVRO), Tactile Systems Technology (TCMD), Beauty Health (SKIN), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Electromed (ELMD), AVITA Medical (RCEL), Perspective Therapeutics (CATX), Inogen (INGN), and Lakeland Industries (LAKE). These companies are all part of the "medical equipment" industry.
Outset Medical vs.
Nevro (NYSE:NVRO) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, community ranking, dividends and earnings.
Nevro currently has a consensus target price of $5.36, suggesting a potential downside of 8.29%. Outset Medical has a consensus target price of $27.00, suggesting a potential upside of 45.16%. Given Outset Medical's stronger consensus rating and higher possible upside, analysts plainly believe Outset Medical is more favorable than Nevro.
Nevro has a net margin of -16.54% compared to Outset Medical's net margin of -112.57%. Nevro's return on equity of -23.52% beat Outset Medical's return on equity.
Nevro has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Nevro received 479 more outperform votes than Outset Medical when rated by MarketBeat users. Likewise, 62.07% of users gave Nevro an outperform vote while only 37.88% of users gave Outset Medical an outperform vote.
95.5% of Nevro shares are held by institutional investors. 3.2% of Nevro shares are held by company insiders. Comparatively, 2.4% of Outset Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Nevro has higher revenue and earnings than Outset Medical. Nevro is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Outset Medical had 6 more articles in the media than Nevro. MarketBeat recorded 7 mentions for Outset Medical and 1 mentions for Nevro. Outset Medical's average media sentiment score of 0.07 beat Nevro's score of 0.00 indicating that Outset Medical is being referred to more favorably in the news media.
Summary
Nevro beats Outset Medical on 11 of the 18 factors compared between the two stocks.
Get Outset Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Outset Medical Competitors List
Related Companies and Tools
This page (NASDAQ:OM) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy OM Stock Free OM Stock Alerts